#eli-lilly

#eli-lilly

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.

Eli Lilly's new obesity and diabetes drug 'orforglipron' faces challenges due to its complicated name.

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

Eli Lilly aims to become the first healthcare company with a $1 trillion market cap, spurred by its GLP-1 therapy leadership.

Orforglipron's success in trials positions Lilly for significant market growth in obesity and diabetes management.

Eli Lilly's stock has risen 464.44% since 2020, indicating strong growth potential and key clinical advancements shaping its future.

With a focus on research in oncology and diabetes prevention, Eli Lilly is well-positioned for sustained growth in the coming years.

Eli Lilly's stock has seen remarkable growth recently, with a projected positive future driven by innovations and strategic investments.

Eli Lilly's Zepbound missed sales estimates, raising concerns over the demand for popular weight loss drugs.

Eli Lilly's stock has increased dramatically since 2020, reflecting strong future growth potential.

Eli Lilly's stock has risen dramatically, but future estimates depend on revenue projections and strategic partnerships.

Eli Lilly will sell weight loss drug Zepbound directly to consumers via LillyDirect, offering an affordable option for those without insurance.

Zepbound is the first ever FDA-approved medication for treating obstructive sleep apnea, particularly aimed at those with obesity.

Eli Lilly is introducing lower-cost single-use vials of Zepbound to meet demand and improve accessibility for weight-loss medications.

Eli Lilly launches Zepbound vials at lower prices to address supply shortages and boost access for patients.

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly's new Zepbound vials improve drug access and affordability despite increased user difficulty compared to autoinjector pens.

Eli Lilly's stock surged 635% from late 2020 to summer 2024, driven by innovation and regulatory success.

Pharmaceutical stocks are relatively stable during economic downturns, appealing to long-term investors despite drug pricing concerns.

Eli Lilly's orforglipron shows significant weight loss for Type 2 diabetes patients, potentially rivaling injectable medications.

Lilly's shares surged 15% following promising clinical trial results for orforglipron.

Eli Lilly warns against fake and compounded diabetes and weight loss drugs, addresses concerns of shortages and health risks.

FDA advisers backed Alzheimer's drug from Eli Lilly, suggesting approval for mild dementia treatment.

The FDA approved a new Alzheimer's treatment, donanemab, by Eli Lilly, aiming to slow brain decline in early-stage patients.

Eli Lilly has appointed R/GA to manage social media for its Zepbound weight-loss drug and other brands.

FDA approval of Zepbound opens a new market for Eli Lilly in sleep apnea treatment.

The FDA's decision to change a prior ruling alleviated patient access issues but raised safety concerns regarding compounded drugs.

Hims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.